Effects of omega-3 fatty acid supplements on serum lipids, apolipoproteins and malondialdehyde in type 2 diabetes patients

East Mediterr Health J. Mar-Apr 2008;14(2):305-13.

Abstract

In order to test whether hyperlipidaemia and glycaemic control can be improved among diabetes patients by dietary supplementation with purified omega-3 fatty acids, we carried out a double-blind, placebo-controlled trial on 50 type 2 diabetes patients randomized to 2 g/day purified omega-3 fatty acids or placebo for 10 weeks. Fasting triglycerides decreased significantly with supplementation relative to placebo (P = 0.01). There was a significant decrease in ApoB-100 and malondialdehyde compared to baseline values and compared to the control group. Omega-3 fatty acids had no significant effect on serum lipid levels, ApoA-I, glucose, insulin and HbA1c.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Analysis of Variance
  • Apolipoproteins / blood*
  • Apolipoproteins / drug effects
  • Body Mass Index
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetes Mellitus, Type 2 / metabolism
  • Dietary Supplements
  • Double-Blind Method
  • Fatty Acids, Omega-3 / pharmacology
  • Fatty Acids, Omega-3 / therapeutic use*
  • Female
  • Glycated Hemoglobin A / drug effects
  • Glycated Hemoglobin A / metabolism
  • Humans
  • Hyperlipidemias / blood
  • Hyperlipidemias / complications
  • Hyperlipidemias / prevention & control*
  • Insulin / blood
  • Iran
  • Lipids / blood*
  • Male
  • Malondialdehyde / blood*
  • Middle Aged
  • Statistics, Nonparametric
  • Treatment Outcome
  • Triglycerides / blood

Substances

  • Apolipoproteins
  • Fatty Acids, Omega-3
  • Glycated Hemoglobin A
  • Insulin
  • Lipids
  • Triglycerides
  • Malondialdehyde